RANBP17 and head and neck squamous cell carcinoma: When comparing the survival of HPV+ HNSCC patients carrying RanBP17 high or low (cutoff 50%) expressing HNSCC, a significantly higher cumulative survival is seen for patients with RanBP17 high HPV+ HNSCC.